What is NMRA's current stock price?

NMRA (Neumora Therapeutics, Inc. Common Stock) is currently trading at $1.85 with a market cap of $342.8M.

What sector is Neumora Therapeutics, Inc. Common Stock in?

Neumora Therapeutics, Inc. Common Stock (NMRA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is NMRA a good stock to buy?

Analysts have a Buy consensus on NMRA with a price target of $7.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NMRA Neumora Therapeutics, Inc. Common Stock

Healthcare

$1.85+0.00%ClosedMarket Cap: $342.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.71

P/S

0.00

EV/EBITDA

-0.89

DCF Value

$1.10

FCF Yield

-56.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-181.7%

ROA

-144.5%

ROIC

-179.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-53.5M	$—
Q4 null	$0.00	$-59.5M	$—
FY null	$0.00	$-236.9M	$—
Q3 null	$0.00	$-56.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$6.00 - $8.00

2 Strong Buy5 Buy1 Hold0 Sell1 Strong Sell

GuggenheimBuy

2026-03-31

NeedhamBuy

2026-03-31

William BlairOutperform

2026-02-17

RBC CapitalOutperform

2025-12-01

StifelHold

2025-11-17

Trading Activity

Insider Trades

View All

Pinto Joshuaofficer: President

SellThu Feb 19

Milligan Michael Leeofficer: See Remarks

SellThu Feb 19

BERNS PAUL Ldirector, officer: See Remarks

SellThu Feb 19

Aurora Daljit Singhofficer: See Remarks

SellThu Feb 19

Pinto Joshuaofficer: President

SellFri Jan 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

3.05

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Peers